Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899795 · ClinicalTrials.gov registry record
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers
A clinical trial, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- 35
- Enrollment target
NCT00899795 is a clinical trial that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 35 participants.
The verdict
NCT00899795 has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of bone marrow from patients with cancer and from healthy volunteers in the laboratory may help doctors learn more about changes that occur in bone marrow stromal (connective tissue) cells. It may also help doctors understand the effects of alkylating agents on bone marrow stromal cells. PURPOSE: This laboratory study is evaluating stromal cells in patients with acute myeloid leukemia, myelodysplastic syndromes, or Fanconi anemia; in patients who were exposed to alkylating agents; and in healthy volunteers.
Interventions
- PROCEDURE biopsy
- OTHER flow cytometry
- GENETIC cytogenetic analysis
- GENETIC fluorescence in situ hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2002-06 |
| Est. Completion | 2010-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00899795
The ClinicalTrials.gov registry entry for NCT00899795 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which biopsy is the first listed.
NCT00899795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00899795 about?
NCT00899795 is a clinical study titled "Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers". RATIONALE: Studying samples of bone marrow from patients with cancer and from healthy volunteers in the laboratory may help doctors learn more about changes that occur in bone marrow stromal (connective tissue) cells. It may also help doctors understand the effects of alkylating agents on bone marro...
What is the current status of trial NCT00899795?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2002-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00899795?
The interventions under investigation include: biopsy (PROCEDURE), flow cytometry (OTHER), cytogenetic analysis (GENETIC), fluorescence in situ hybridization (GENETIC).
Who is sponsoring clinical trial NCT00899795?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.